( ASPV) were among the best-performing health-related stocks Thursday, jumping 15% after the company said its first-quarter revenue would be better than expected.
The pharmaceutical company sees first-quarter revenue of about $62 million, well above the $42.3 million that analysts polled by Thomson First Call projected. Results were helped by a higher-than-expected reconciliation payment of $16 million that's associated with the company's collaboration agreement with
. The company now expects royalty revenue to exceed $200 million during 2006. Aspreva plans to issue first-quarter results on April 26. Shares were trading up $3.58 to $27.12.
fell 5% after the company said it expects to post a first-quarter loss. The medical-device maker projects a loss of $1.7 million to $1.9 million, or 3 cents to 4 cents a share, on revenue of about $48.8 million. The estimate includes stock-based compensation costs of $2.3 million to $2.5 million. Analysts forecast a profit of 9 cents a share, which doesn't include stock-based compensation costs, on revenue of $54.3 million. During the year-earlier quarter, the company earned $3.1 million, or 6 cents a share, on revenue of $50.5 million.
"Our first-quarter results are due to several factors that we do not believe reflect the long-term opportunities for the company," Thoratec said. The company said it was hurt by lower North American ventricular-assist device sales and by slower-than-expected enrollment in a Phase II trial studying its Heartmate II device. Shares were down 96 cents to $17.13.
rose 8% after the biosurgical-device company projected better-than-expected revenue for the first quarter and full year. The company sees revenue of $19.4 million, higher than the $18.8 million that analysts project. "We are very pleased with our quarterly revenue performance and expect continued financial improvement throughout 2006," the company said. Last year, the company posted first-quarter revenue of $17.7 million.
CryoLife now sees 2006 revenue of $76 million to $80 million, up from an earlier forecast of $74 million to $77 million. Analysts project revenue of $76.7 million. Shares were trading up 37 cents to $4.84.
( MOGN) rose 3% after the company issued mixed first-quarter projections. The company estimates a loss of 3 cents to 5 cents a share, in line with analysts' expectations. MGI put its revenue at $78 million, which is below the $81.4 million that analysts project. The company said it expects sales of its Aloxi anti-nausea injection to total about $63 million for the quarter. Aloxi sales came in at about $67 million during the fourth quarter of 2005. "The sequential decrease in Aloxi injection sales is primarily due to fewer emetogenic chemotherapy administrations and a continued competitive market," the company said.
Looking ahead, MGI continues to expect Aloxi injection sales of $285 million to $300 million during 2006, as chemotherapy administration returns to normal levels during the second, third and fourth quarters. Shares, which dipped in early trading, were recently up 55 cents to $16.68.
Other health care volume movers included
, down $1.06 to $49.98;
, down 49 cents to $21.67;
, up 8 cents to $24.50;
St. Jude Medical
, down $1.18 to $35.67;
Bausch & Lomb
( BOL), up 80 cents to $46.41;
, up 4 cents to $53.50;
, up 10 cents to $5.56;
, down 18 cents to $69.79;
, up 3 cents to $33.88;
Johnson & Johnson
, up 2 cents to $57.89;
, up 6 cents to $2.71;
, up 12 cents to $24.18; and
( SGP), down 23 cents to $18.32.